Supernus Pharmaceuticals, Inc. has officially completed its merger with Indivior Pharmaceuticals, Inc., a significant event that marks a new chapter for both companies. This merger not only alters Supernus's corporate structure but also impacts its status as a public company, as it will cease to be publicly traded following the merger.

The merger was finalized on November 2, 2026, when Indivior's subsidiary merged with Supernus, making Supernus a wholly owned subsidiary of Indivior. This strategic move is expected to enhance Indivior's position in the pharmaceutical industry, particularly in the pharmaceutical preparations sector.

Background

Supernus Pharmaceuticals, Inc. operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol SUPN. As a large accelerated filer, Supernus has been involved in various filings, including recent forms such as 10-Q and 8-K, with the latest being filed on November 2, 2026.

What the Filing Says

In the recent filing, Supernus stated, "The Company has ceased to be a public reporting company, the Common Stock is being delisted from the Nasdaq Global Market and deregistered under the Securities Exchange Act of 1934, as amended." This indicates a complete transition to private ownership under Indivior.

Impact

This merger affects shareholders of Supernus, who will now receive shares of Indivior's common stock in exchange for their holdings. Each share of Supernus common stock was converted into the right to receive 1.5401 shares of Indivior's common stock. The merger may also influence competitors in the pharmaceutical preparations industry, as Indivior aims to leverage Supernus's portfolio and capabilities.

What's Next

Following this merger, Supernus will no longer operate as a public entity, and the filing does not specify any further actions or upcoming filings related to the transition.

This merger represents a significant consolidation in the pharmaceutical industry, with potential implications for market dynamics and competition in the sector.